Ladenburg Thalmann Financial Services Inc. raised its holdings in Stryker Co. (NYSE:SYK) by 22.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 54,250 shares of the medical technology company’s stock after buying an additional 9,902 shares during the quarter. Ladenburg Thalmann Financial Services Inc.’s holdings in Stryker were worth $11,261,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Tiedemann Advisors LLC acquired a new position in shares of Stryker in the 4th quarter valued at about $969,000. Point72 Hong Kong Ltd purchased a new position in Stryker during the fourth quarter valued at approximately $474,000. Point72 Asset Management L.P. purchased a new position in Stryker during the fourth quarter valued at approximately $69,856,000. Advisors Asset Management Inc. lifted its holdings in Stryker by 1.1% in the fourth quarter. Advisors Asset Management Inc. now owns 16,124 shares of the medical technology company’s stock valued at $3,385,000 after acquiring an additional 180 shares during the period. Finally, Captrust Financial Advisors lifted its holdings in Stryker by 1,551.4% in the fourth quarter. Captrust Financial Advisors now owns 29,411 shares of the medical technology company’s stock valued at $6,206,000 after acquiring an additional 27,630 shares during the period. 73.10% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE SYK opened at $153.05 on Thursday. The firm has a market cap of $53.73 billion, a price-to-earnings ratio of 27.93, a price-to-earnings-growth ratio of 1.56 and a beta of 0.80. The company’s 50-day simple moving average is $191.15 and its 200-day simple moving average is $205.62. The company has a quick ratio of 1.84, a current ratio of 2.58 and a debt-to-equity ratio of 0.80. Stryker Co. has a 52-week low of $124.54 and a 52-week high of $226.30.
Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.46 by $0.03. The firm had revenue of $4.13 billion during the quarter, compared to the consensus estimate of $4.11 billion. Stryker had a net margin of 13.99% and a return on equity of 25.75%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.18 EPS. Equities research analysts anticipate that Stryker Co. will post 9.11 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a $0.575 dividend. The ex-dividend date is Monday, March 30th. This represents a $2.30 annualized dividend and a dividend yield of 1.50%. Stryker’s dividend payout ratio (DPR) is presently 27.85%.
Several equities analysts have recently weighed in on SYK shares. Deutsche Bank lifted their target price on shares of Stryker from $239.00 to $243.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Robert W. Baird increased their price target on shares of Stryker from $242.00 to $248.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. BTIG Research restated a “buy” rating on shares of Stryker in a research report on Thursday, January 30th. Cantor Fitzgerald restated a “neutral” rating on shares of Stryker in a research report on Wednesday, January 29th. Finally, Piper Sandler cut shares of Stryker from an “overweight” rating to a “neutral” rating and set a $210.00 price objective for the company. in a report on Tuesday, January 7th. Seven investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $220.81.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Further Reading: Net Margin – Understanding the Different Kinds of Profit
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.